Safety of lornoxicam in G-6-PDH deficiency

Objective: To assess the safety of lornoxicam in subjects with G-6-PDH deficiency. Methods: Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases. Results: In 8 male patients with the Mediterranean form of G-6-PDH deficiency (mean age ± SD, 54.3 years ± 7.2) lornoxicam showed no influence on red blood cells (RBC) survival curve. The RBC half-life was the same before and after two weeks of treatment. Conclusions: Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases

Markers of bone resorption in bisphosphonate therapy of Paget’s disease

Bone turnover markers are used both in diagnosis and in therapeutic monitoring of Paget's disease. We studied 10 patients with poliostotic Paget's disease treated with risendronate (30 mg/day for 2 months)in order to evaluate the usefullness of seruma CTx, serum NTx and urine NTx as parameters of bone resorption in the management of therapy. The bone turnover markers were evaluated at baseline and 30 days after therapy. A significant reduction in the markers of bone resorption and neoformation was demonstrated. Our study shows that serum CTx is a sensitive marker of bone resorption in the management of bisphosphonate therapy in Paget's disease

Efficacia dell’etoricoxib nell’attacco acuto di gotta

Scopo dello studio e' valutare l'efficacia e la tollerabilità dell'etoricoxib 120 mg/die nell'attacco acuto di gotta. Abbiamo esaminato 10 pazienti con diagnosi di gotta. I valori medi degli indici di flogosi erano aumentati. tutti i pazienti sono stati trattati con il farmaco. Dopo 1 settimana gli indici di flogosi sono ritornati nella norma